2-[(4-chlorobenzoyl)amino]-5-iodobenzoic acid | 901290-21-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-[(4-chlorobenzoyl)amino]-5-iodobenzoic acid
• 英文别名: 2‐(4‐chlorobenzamido)‐5‐iodobenzoic acid
• CAS: 901290-21-9
• 化学式: C₁₄H₉ClINO₃
• 分子量: 401.588
• InChiKey: MLCTZFOLHKQZRX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  66.4
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-[(4-chlorobenzoyl)amino]-5-iodobenzoic acid 在 乙酸酐 作用下， 生成 2-(4-chlorophenyl)-6-iodo-4H-3,1-benzoxazin-4-one
  参考文献：
  名称：

  一些新型喹唑啉衍生物的合成，镇痛和抗炎作用

  摘要：

  制备了两个系列的一些新的2,4,6-三取代喹唑啉衍生物，并对其镇痛，抗炎活性和急性毒性进行了筛选。四种化合物比参考药物消炎痛更有效的镇痛药，十三种化合物表现出显着的抗炎活性。七种化合物具有抑制疼痛和炎症的综合能力。化合物经急性毒性测试后，给药后24小时无毒性症状或死亡率，这表明它们具有良好的安全性。

  DOI：

  10.1016/j.ejmech.2010.07.067
• 作为产物：
  描述：

  对氯苯甲酸 在 sodium carbonate 、 三乙胺 作用下， 以 四氢呋喃 、 水 、 甲苯 为溶剂， 生成 2-[(4-chlorobenzoyl)amino]-5-iodobenzoic acid
  参考文献：
  名称：

  通过基于片段的筛选发现首个结核分枝杆菌MabA（FabG1）抑制剂。

  摘要：

  结核分枝杆菌（M.tb）是结核病的病原体，仍然是全球单一传染病致死的主要原因。耐药性结核分枝杆菌的出现菌株强调需要药物作用于新靶标。分枝杆菌酸是很长的链脂肪酸，在分枝杆菌细胞壁的结构和渗透性中起着至关重要的作用。它们的生物合成涉及两个脂肪酸合酶（FAS）系统。在FAS-II周期的四种酶（MabA，HadAB / BC，InhA和KasA / B）中，MabA（FabG1）仍然是唯一尚未报道特异性抑制剂的酶。新的基于LC-MS / MS的酶促测定方法的开发，可以筛选1280个片段文库，并导致发现了第一个抑制MabA活性的小分子。将邻氨基苯甲酸系列的片段优化为更有效的抑制剂，并通过19 F配体观察的NMR实验证实了它们与MabA的结合。

  DOI：

  10.1016/j.ejmech.2020.112440

文献信息

• 10.1002/ardp.202400389
  作者：Alsulaimany, Marwa、El-Hddad, Sanadelaslam S. A.、Akrim, Zuhir S. M.、Aljohani, Ahmed K. B.、Almohaywi, Basmah、Alatawi, Omar M.、Almadani, Sara A.、Alharbi, Hussam Y.、Aljohani, Majed S.、Miski, Samar F.、Alghamdi, Read、El-Adl, Khaled

  DOI：10.1002/ardp.202400389

  日期：——

  AbstractNovel inhibitors of epidermal growth factor receptor (EGFR)T790M/vascular endothelial growth factor receptor‐2 (VEGFR‐2) were synthesized based on the iodoquinazoline scaffold linked to different heteroaromatic, aromatic, and/or aliphatic moieties. The novel derivatives were in vitro examined for anticancer activities against A549, HCT116, michigan cancer foundation‐7 (MCF‐7), and HepG2 cells. Molecular modeling was applied to discover their orientation of binding with both VEGFR‐2 and EGFR active sites. Compounds 8d, 8c, 6d, and 6c indicated the highest cytotoxicity with IC50 = 6.00, 6.90, 6.12 and 6.24 µM, 7.05, 7.35, 6.80, and 6.80 µM, 5.75, 7.50, 6.90, and 6.95 µM, and 6.55, 7.88, 7.44, and 7.10 µM against the A549, HepG2, HCT116, and MCF‐7 cell lines, correspondingly. The cytotoxicity against normal VERO (normal african green monkey kidney cells) of the extremely active eight compounds 6a–d and 8a–d was evaluated. Our compounds exhibited low toxicity concerning normal VERO cells with IC50 = 45.66–51.83 μM. Furthermore, inhibition assays for both the EGFRT790M and VEGFR‐2 enzymes were done for all compounds. Remarkable inhibition of EGFRT790M activity was achieved with compounds 6d, 8d, 6c, and 8c at IC50 = 0.35, 0.42, 0.48, and 0.50 µM correspondingly. Moreover, remarkable inhibition of VEGFR‐2 activity was achieved with compounds 8d, 8c, 6d, and 6c at IC50 = 0.92, 0.95, 1.00, and 1.20 µM correspondingly. As planned, derivatives 6d, 8d, 6c, and 8c presented exceptional inhibition of both EGFRT790M/VEGFR‐2 activities. Finally, in silico absorption, distribution, metabolism, excretion and toxicity (ADMET) studies were made for the highly active four compounds 6c, 6d, 8c, and 8d in comparison with erlotinib and sorafenib as reference standards.
• Discovery of the first Mycobacterium tuberculosis MabA (FabG1) inhibitors through a fragment-based screening
  作者：Léo Faïon、Kamel Djaout、Rosangela Frita、Catalin Pintiala、Francois-Xavier Cantrelle、Martin Moune、Alexandre Vandeputte、Kevin Bourbiaux、Catherine Piveteau、Adrien Herledan、Alexandre Biela、Florence Leroux、Laurent Kremer、Mickael Blaise、Abdalkarim Tanina、René Wintjens、Xavier Hanoulle、Benoit Déprez、Nicolas Willand、Alain R. Baulard、Marion Flipo

  DOI：10.1016/j.ejmech.2020.112440

  日期：2020.8

  Mycobacterium tuberculosis (M.tb), the etiologic agent of tuberculosis, remains the leading cause of death from a single infectious agent worldwide. The emergence of drug-resistant M.tb strains stresses the need for drugs acting on new targets. Mycolic acids are very long chain fatty acids playing an essential role in the architecture and permeability of the mycobacterial cell wall. Their biosynthesis

  结核分枝杆菌（M.tb）是结核病的病原体，仍然是全球单一传染病致死的主要原因。耐药性结核分枝杆菌的出现菌株强调需要药物作用于新靶标。分枝杆菌酸是很长的链脂肪酸，在分枝杆菌细胞壁的结构和渗透性中起着至关重要的作用。它们的生物合成涉及两个脂肪酸合酶（FAS）系统。在FAS-II周期的四种酶（MabA，HadAB / BC，InhA和KasA / B）中，MabA（FabG1）仍然是唯一尚未报道特异性抑制剂的酶。新的基于LC-MS / MS的酶促测定方法的开发，可以筛选1280个片段文库，并导致发现了第一个抑制MabA活性的小分子。将邻氨基苯甲酸系列的片段优化为更有效的抑制剂，并通过19 F配体观察的NMR实验证实了它们与MabA的结合。
• Synthesis, analgesic and anti-inflammatory evaluation of some novel quinazoline derivatives
  作者：Ahmed M. Alafeefy、Adnan A. Kadi、Omar A. Al-Deeb、Kamal E.H. El-Tahir、Nabila A. Al-jaber

  DOI：10.1016/j.ejmech.2010.07.067

  日期：2010.11

  Two series of some new 2,4,6-trisubstituted-quinazoline derivatives were prepared and screened for their analgesic, anti-inflammatory activity and acute toxicity. Four compounds were more potent analgesic agents than the reference drug Indomethacin and thirteen compounds showed significant anti-inflammatory activity. Seven compounds showed combined ability to inhibit both pain and inflammation. Compounds

  制备了两个系列的一些新的2,4,6-三取代喹唑啉衍生物，并对其镇痛，抗炎活性和急性毒性进行了筛选。四种化合物比参考药物消炎痛更有效的镇痛药，十三种化合物表现出显着的抗炎活性。七种化合物具有抑制疼痛和炎症的综合能力。化合物经急性毒性测试后，给药后24小时无毒性症状或死亡率，这表明它们具有良好的安全性。